Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL903627 | 0.80 | PDXK (0.42) | PDXKKDM4EALDH1A1RECQLKMT2A | |
| SCHEMBL30416243 | 0.78 | KDM4E (0.33) | PDXKKDM4EALDH1A1RECQLKMT2A | |
| SCHEMBL13723686 | 0.78 | ALDH1A1 (0.37) | PDXKKDM4EALDH1A1RECQLKMT2A | |
| SCHEMBL3948804 | 0.78 | CYP2D6 (0.37) | PDXKKDM4EALDH1A1RECQLKMT2A | |
| SCHEMBL18703689 | 0.78 | KDM4E (0.33) | PDXKKDM4EALDH1A1RECQLKMT2A | |
| SCHEMBL11001556 | 0.77 | SMN1; SMN2 (0.34) | KDM4EALDH1A1KMT2AMEN1CYP2C19 | |
| SCHEMBL31322990 | 0.72 | TUBB4A (0.36) | KDM4EALDH1A1RECQLKMT2AMEN1 | |
| SCHEMBL903616 | 0.71 | PDXK (0.35) | PDXKCYP2D6CYP2C19 | |
| SCHEMBL14671962 | 0.70 | KDM4E (0.44) | KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL30968506 | 0.70 | KDM4E (0.40) | PDXKKDM4EALDH1A1RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1203760-B1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-6706910-B2 | BY TRANSESTERIFICATION OF A CYCLOPROPANECARBOXYLATE AND A MONOHYDROXY COMPOUND IN THE PRESENCE OF A LITHIUM ALKOXIDE OR LITHIUM ARYLOXIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-03-16 | — | — | US | disclosed |
| EP-1203760-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052525-A1 | Method for producing cyclopropanecarboxylates | CYP8B1, SRD5A2, CYP21A2 | PDXK 2152/4885KDM4E 641/4885ALDH1A1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.